Back

Temporal trend of hemodynamic functional indices in isolated PVAD and combined therapy with VA-ECMO

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pathophysiological mechanisms in heart failure: novel insights Haemodynamics of Heart Failure ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Kanako Teramoto

National Cerebral and Cardiovascular Center Hospital, Osaka (Japan)

7 More presentations in this session

Presentation thumbnail
Sympathetic vasoconstrictor constraint on exercise capacity in heart failure: does biological sex matter?
Doctor M. Badrov (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Relationship between pulmonary artery wedge pressure and left atrial pressure: pathophysiologic implications
Doctor A. Tada (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Predicting factors of right ventricular-pulmonary artery uncoupling assessed by TAPSE/PASP ratio after discharge in patients with heart failure and mildly reduced ejection fraction
Doctor M. Ono (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Interventricular septum displacement and hemodynamic evaluation across heart failure spectrum during exercise performance
Doctor G. Crisci (Hasselt, BE)
Abstract Slides Video
Presentation thumbnail
Effects on mitral and tricuspid valve regurgitation after 6 months of treatment with SGLT2 inhibitors in patients with chronic heart failure
Doctor P. Basile (Bari, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiological mechanisms in heart failure: novel insights

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Trends in mechanical circulatory support use and outcomes of patients with cardiogenic shock in Japan, 2010-2020: a nationwide inpatient database study
thumbnail
Congress Presentation
Impact on the right ventricle during left ventricular unloading with Impella in patients with cardiogenic shock
thumbnail
Congress Presentation
Vasoactive medication requirements in the first 24 hours of cardiogenic shock: association with mortality and mechanical circulatory support

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources